Biofrontera AG delivered USD 7.84 million in revenue for Q2 2024, representing a YoY increase of 34.0% but a QoQ decline of 0.8%. The gross margin stood at approximately 44.6%, with gross profit of USD 3.50 million. Despite a positive EBITDA of USD 0.69 million, the company recorded a substantial operating loss of USD 5.07 million, driven predominantly by selling, general, and administrative expenses (SG&A) totaling USD 7.95 million and R&D expenditure of USD 0.62 million. Net income was negative USD 0.26 million, with earnings per share of -0.0505. The quarterly cash flow from operations was -USD 4.72 million, while financing activity contributed USD 5.28 million—primarily from common stock issuance—leaving the company with USD 4.38 million in cash at period end. Biofrontera remains net debt negative (net debt of -USD 2.94 million) due to its cash position, and maintains a solid current ratio of 2.19.